Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Search PHGKB:

Last Posted: Dec 06, 2023
spot light Highlights

Lipoprotein(a), platelet function and cardiovascular disease.
Harpreet S Bhatia et al. Nat Rev Cardiol 2023 11

From the abstract: " Lipoprotein(a) (Lp(a)) independently contributes to atherothrombosis through several mechanisms, including putative antifibrinolytic properties. However, genetic association studies and experimental studies have not demonstrated an association between high Lp(a) levels in the plasma and the risk of venous thromboembolism or clot properties, respectively."

Identifying individuals at extreme risk of venous thromboembolism using polygenic risk scores.
Michael Chong et al. Nature genetics 2023 3 (3) 358-360

Current risk assessment and treatment strategies for venous thromboembolism (VTE) consider genetic factors only in a limited way. New work shows a more pervasive role of common variants in VTE risk, inspiring genetic predictors that surpass and complement individual clinical risk factors and monogenic thrombophilia testing.

Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism.
Ghouse Jonas et al. Nature genetics 2023 1

We report a genome-wide association study of venous thromboembolism (VTE) incorporating 81,190?cases and 1,419,671?controls sampled from six cohorts. We identify 93?risk loci, of which 62 are previously unreported. Many of the identified risk loci are at genes encoding proteins with functions converging on the coagulation cascade or platelet function. A VTE polygenic risk score (PRS) enabled effective identification of both high- and low-risk individuals.

Association of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism.
Berry Alexander S F et al. JAMA 2023 1 (3) 235-243

In this retrospective multicohort study that included 642?544 adult participants, the incidence of a VTE diagnosis among those with an additional sex chromosome compared with those with 2 sex chromosomes was 1.3% per person-year compared with 0.25% per person-year, respectively, in one cohort, and 0.42% per person-year compared with 0.11% per person-year, respectively, in the other cohort. These differences were statistically significant.

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.